A unique collaboration that will pioneer world-leading research into vital new drugs for both patients and the environment, has been announced by the University of Exeter.
The £2 million partnership with pharmaceutical giant AstraZeneca, which has been the subject of a £60 billion-plus deal by US drug giant Pfizer, will reinforce Exeter's burgeoning reputation as a world-leader in ecotoxicological research.
It will also provide a significant economic boost by securing a number of highly-skilled jobs on the university's Streatham Campus and keeping valuable scientific knowledge in the region.
Professor Nick Talbot, deputy vice-chancellor for research at the University of Exeter, said: "Our research is already making a difference across the world, in ensuring that we understand the fate of chemicals in the environment and how to help manufacture safe and environmentally responsible products.
"This new partnership with AstraZeneca will ensure we remain at the forefront of ecotoxicology and sustainability research with a recognised leader in the field."
Under the terms of the agreement, four scientists currently employed at AstraZeneca's Brixham Environmental Laboratory site, together with a further scientist from Sweden and two PhD students will join world-leading research staff in the university's College of Life and Environmental Sciences.
The new partnership comes after AstraZenecasaid it would close the Brixham Environmental Laboratory. It then announced it was donating the laboratoryto Plymouth University.